CareFusion suing Hospira over drug delivery patents

By Nick Taylor

- Last updated on GMT

Related tags Drug delivery Patent application

CareFusion is suing Hospira and seeking damages over alleged infringement of patents protecting its drug delivery systems.

In documents filed with the court CareFusion asks for a permanent ban on further infringement of two patents. CareFusion claims Hospira is wilfully infringing the patents by selling several products in the US.

The evidence will likely show that [Hospira] has acted with disregard of CareFusion’s patent rights, without any reasonable basis for doing so​”, the complainant said in a filing, 11-762, with the Delaware District Court.

As compensation, CareFusion is seeking “damages and costs, including lost profits and interest​” related to the use of Symbiq, Plum A+ and LifeCare PCA in conjunction with care management systems. CareFusion claims Hospira infringes two of its patents by selling the systems within the US.

The patents, 7,171,277​ and 7,835,927​, cover the automation and management of drug delivery. Between them the patents cover technology to make sure a delivery system has the right administration parameters, check the process and trigger alarms when necessary.

Hospira plans to fight the case. Tareta Adams, a Hospira spokesperson, told Bloomberg​: “We think we’ve got a strong position in this suit and our plan is to vigorously defend it​.”

B Braun suing CareFusion

Days before the case was brought against Hospira, B Braun Medical filed a patent infringement suit against CareFusion. The case covers patents for several products, including an intravenous drug delivery system and security infusion pump with bar code reader.

"This lawsuit was necessary to protect B. Braun's highly valuable technology and patent rights​”, Gale White, vice president of infusion systems at B Braun, said.

Related topics Drug Delivery Delivery technologies

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more